{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:09:46Z","timestamp":1791425386255,"version":"4.3.3"},"reference-count":48,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a phase 1\/2 two-arm trial, 54 patients with myeloma received autografts followed by ex vivo anti-CD3\/anti-CD28 costimulated autologous T cells at day 2 after transplantation. Study patients positive for human leukocyte antigen A2 (arm A, n = 28) also received pneumococcal conjugate vaccine immunizations before and after transplantation and a multipeptide tumor antigen vaccine derived from the human telomerase reverse transcriptase and the antiapoptotic protein survivin. Patients negative for human leukocyte antigen A2 (arm B, n = 26) received the pneumococcal conjugate vaccine only. Patients exhibited robust T-cell recoveries by day 14 with supraphysiologic T-cell counts accompanied by a sustained reduction in regulatory T cells. The median event-free survival (EFS) for all patients is 20 months (95% confidence interval, 14.6-24.7 months); the projected 3-year overall survival is 83%. A subset of patients in arm A (36%) developed immune responses to the tumor antigen vaccine by tetramer assays, but this cohort did not exhibit better EFS. Higher posttransplantation CD4+ T-cell counts and a lower percentage of FOXP3+ T cells were associated with improved EFS. Patients exhibited accelerated polyclonal immunoglobulin recovery compared with patients without T-cell transfers. Adoptive transfer of tumor antigen vaccine-primed and costimulated T cells leads to augmented and accelerated cellular and humoral immune reconstitution, including antitumor immunity, after autologous stem cell transplantation for myeloma. This study was registered at www.clinicaltrials.gov as NCT00499577.<\/jats:p>","DOI":"10.1182\/blood-2010-08-299396","type":"journal-article","created":{"date-parts":[[2010,10,29]],"date-time":"2010-10-29T04:02:56Z","timestamp":1288324976000},"page":"788-797","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":141,"title":["Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma"],"prefix":"10.1182","volume":"117","author":[{"given":"Aaron P.","family":"Rapoport","sequence":"first","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Aqui","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bin","family":"Fang","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cai","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Janofsky","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chew","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[{"name":"The University of Calgary, Calgary, AB; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorgun","family":"Akpek","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Yanovich","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming T.","family":"Tan","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Veloso","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[{"name":"The University of Maryland Center for Vaccine Development, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cross","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"},{"name":"The University of Maryland Center for Vaccine Development, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Philip","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Murphy","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Milliron","sequence":"additional","affiliation":[{"name":"University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Cotte","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cannon","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111719472667500_B1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111719472667500_B2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111719472667500_B3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111719472667500_B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06271.x","article-title":"Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.","volume":"135","author":"Barlogie","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111719472667500_B5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle.","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"4","key":"2019111719472667500_B6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell\u2013depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111719472667500_B7","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111719472667500_B8","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by a dose-related allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04) trial in high-risk de novo multiple myeloma.","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111719472667500_B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.bmt.1705192","article-title":"Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.","volume":"37","author":"Gojo","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111719472667500_B10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111719472667500_B11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","article-title":"Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111719472667500_B12","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.6004\/jnccn.2010.0113","article-title":"The role of maintenance therapy in the treatment of multiple myeloma.","volume":"8","author":"Badros","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2019111719472667500_B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V98.3.579","article-title":"Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.","volume":"98","author":"Porrata","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111719472667500_B14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2141.2008.07123.x","article-title":"Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.","volume":"141","author":"Ege","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111719472667500_B15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bmt.1705342","article-title":"Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.","volume":"37","author":"Joao","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111719472667500_B16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bbmt.2008.04.013","article-title":"Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.","volume":"14","author":"Porrata","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111719472667500_B17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbmt.2009.10.029","article-title":"New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.","volume":"16","author":"Porrata","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019111719472667500_B18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ajh.21618","article-title":"Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.","volume":"85","author":"Jacobs","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111719472667500_B19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.21337","article-title":"Absolute lymphocyte count at the time of the first relapse predicts survival in patients with diffuse large B-cell lymphoma.","volume":"84","author":"Porrata","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111719472667500_B20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V92.5.1471","article-title":"Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.","volume":"92","author":"Guillaume","year":"1998","journal-title":"Blood"},{"issue":"7","key":"2019111719472667500_B21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1703228","article-title":"Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with aBMT. Serological responses to revaccinations according to EBMT guidelines.","volume":"28","author":"Nordoy","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"5403","key":"2019111719472667500_B22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.283.5403.848","article-title":"CD3- and CD28-dependent induction of PDE7 required for T cell activation.","volume":"283","author":"Li","year":"1999","journal-title":"Science"},{"issue":"3","key":"2019111719472667500_B23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/73144","article-title":"p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes.","volume":"6","author":"Boussiotis","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"2019111719472667500_B24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/intimm\/7.6.891","article-title":"CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro.","volume":"7","author":"Levine","year":"1995","journal-title":"International Immunology"},{"issue":"12","key":"2019111719472667500_B25","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.","volume":"159","author":"Levine","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"2019111719472667500_B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111719472667500_B27","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nm1310","article-title":"Restoration of Immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.","volume":"11","author":"Rapoport","year":"2005","journal-title":"Nat Med"},{"key":"2019111719472667500_B28","article-title":"Transfer of influenza vaccine-primed costimulated autologous T-Cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.","author":"Stadtmauer","journal-title":"Blood"},{"issue":"5","key":"2019111719472667500_B29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1054\/bjoc.2000.1655","article-title":"Telomerase activity in plasma cell dyscrasias.","volume":"84","author":"Xu","year":"2001","journal-title":"Br J Cancer"},{"issue":"12","key":"2019111719472667500_B30","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1182\/blood-2002-11-3451","article-title":"Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetics status, and overall survival.","volume":"101","author":"Wu","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111719472667500_B31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.leu.2404602","article-title":"Significant impact of survivin on myeloma cell growth.","volume":"21","author":"Romagnoli","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2019111719472667500_B32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2009.07608.x","article-title":"The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.","volume":"145","author":"Romagnoli","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111719472667500_B33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2249.2005.02879.x","article-title":"Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.","volume":"141","author":"Maecker","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2019111719472667500_B34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1158\/1078-0432.CCR-06-1722","article-title":"CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.","volume":"13","author":"Grube","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111719472667500_B35","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","article-title":"Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells.","volume":"15","author":"Rapoport","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111719472667500_B36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1074-7613(00)80066-7","article-title":"The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.","volume":"10","author":"Vonderheide","year":"1999","journal-title":"Immunity"},{"issue":"11","key":"2019111719472667500_B37","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.4049\/jimmunol.168.11.5900","article-title":"HER-2\/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.","volume":"168","author":"Scardino","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"2019111719472667500_B38","first-page":"869","article-title":"Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.","volume":"61","author":"Andersen","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"2019111719472667500_B39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmv.1890430119","article-title":"Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.","volume":"43","author":"McLaughlin-Taylor","year":"1994","journal-title":"J Med Virol"},{"issue":"6","key":"2019111719472667500_B40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/14653240410005348","article-title":"GMP production and testing of Xcellerated T cells for the treatment of patients with CLL.","volume":"6","author":"Hami","year":"2005","journal-title":"Cytotherapy"},{"issue":"21","key":"2019111719472667500_B41","doi-asserted-by":"crossref","first-page":"10546","DOI":"10.1158\/0008-5472.CAN-07-2765","article-title":"Telomerase-specific T-cell immunity in breast cancer: Effect of vaccination on tumor immunosurveillance.","volume":"67","author":"Domchek","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"2019111719472667500_B42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.0006-341X.2002.00612.x","article-title":"Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.","volume":"58","author":"Tan","year":"2002","journal-title":"Biometrics"},{"key":"2019111719472667500_B43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy of cancer.","volume":"27","author":"Dougan","year":"2009","journal-title":"Ann Rev Immunol"},{"issue":"7","key":"2019111719472667500_B44","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma \u2013 a feasibility study.","volume":"93","author":"Reichardt","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2019111719472667500_B45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.leu.2403181","article-title":"Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.","volume":"18","author":"Coscia","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"2019111719472667500_B46","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.onc.1202458","article-title":"Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections.","volume":"18","author":"Tahara","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"2019111719472667500_B47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/hupa.2001.21897","article-title":"Expression of surviving in normal, hyperplastic, and neoplastic colonic mucosa.","volume":"32","author":"Gianani","year":"2001","journal-title":"Hum Pathol"},{"issue":"11","key":"2019111719472667500_B48","doi-asserted-by":"crossref","first-page":"956a","DOI":"10.1182\/blood.V112.11.2772.2772","article-title":"The immunomodulatory role of lenalidomide on Prevnar\u00ae responses in patients with relapsed multiple myeloma: a comprehensive analysis of the immune response [abstract].","volume":"112","author":"Noonan","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/3\/788\/1462869\/zh800311000788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/3\/788\/1462869\/zh800311000788.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T21:53:05Z","timestamp":1711921985000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/3\/788\/125521\/Combination-immunotherapy-using-adoptive-Tcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,20]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,1,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-08-299396","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,20]]}}}